New Issue: Science’s Impossible Questions. Read Now

How Medication Abortion with RU-486/Mifepristone Works

A step-by-step look at how these drugs end pregnancy

Detail of graphic shows how mifepristone and misoprostol act on the uterus and cervix to expel the embryo and endometrium.

Mesa Schumacher

Join Our Community of Science Lovers!

Editor’s Note (4/10/23): On Friday a federal judge in Texas ordered a hold on federal approval of the abortion drug mifepristone, which has been approved by the Food and Drug Administration for more than 20 years. The ruling is set to take effect within seven days of that order. On the same day a federal judge in Washington State ruled that no changes can be made to the drug’s availability in 17 states where abortion is legal or in Washington, D.C. This article, originally published in May 2022, describes how mifepristone works in concert with another drug, misoprostol, to end a pregnancy. 

In 2016 the U.S. Food and Drug Administration approved a two-drug combination of Mifeprex (also called RU-486 or mifepristone) and Cytotec (commonly known as misoprostol) to induce abortion without surgery. In 2019 the Centers for Disease Control and Prevention reported that approximately 42 percent of all abortions in the U.S. were medication-based.

To start the process, a person takes mifepristone within 10 weeks from their last period. One or two days later they take misoprostol. Both drugs work individually, but they are more effective together. Mifepristone blocks progesterone's action on the uterus, making it incapable of supporting a pregnancy. Misoprostol, among other things, starts uterine contractions.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Credit: Mesa Schumacher

Research has shown medication abortion to be safe and effective. According to a 2015 study from the University of California, Los Angeles, 99.6 percent of more than 30,000 women who were seeking a medication abortion were able to terminate their pregnancies. In a review of clinical trials published in 2013, using mifepristone and misoprostol together, just 0.3 percent of the more than 45,000 women studied had complications that required hospitalization. The treatment did occasionally fail if the pregnancy was longer than eight weeks or if the instructions weren't followed. The mortality rate of the medications is less than 0.001 percent.

Megha Satyanarayana is chief special projects editor at Scientific American. She is a former scientist who has worked at several news outlets, including the Detroit Free Press and STAT. She was a Knight-Wallace Fellow, a cohort member of Poynter’s Leadership Academy for Women in Digital Media and a Maynard 200 Fellow.

More by Megha Satyanarayana

Mesa Schumacher is a medical illustrator and science artist with a passion for clear communication and engaging visuals. She is the principal artist of Mesa Studios. Her work can be found in magazines, books, journals, museums, zoos, aquariums and educational games.

More by Mesa Schumacher
Scientific American Magazine Vol 327 Issue 3This article was published with the title “How Medication Abortion Works” in Scientific American Magazine Vol. 327 No. 3 (), p. 80
doi:10.1038/scientificamerican0922-80

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe